OTCMKTS:BVNRY - BAVARIAN NORDIC/S Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $9.31 +0.67 (+7.75 %) (As of 09/21/2018 02:33 PM ET)Previous Close$8.6438Today's Range$9.31 - $9.3152-Week Range$8.63 - $15.59Volume469 shsAverage Volume248 shsMarket Capitalization$837.84 millionP/E Ratio32.10Dividend YieldN/ABeta0.62 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus. In addition, the company is developing PROSTVAC, which is in Phase III clinical development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer; CV301 that is in Phase II clinical trial for the treatment multiple cancers; and MVA-BN Brachyury that has completed Phase I clinical trial for the treatment of metastatic cancer. The company has collaboration agreements with National Cancer Institute; Bristol-Myers Squibb; Janssen Pharmaceuticals, Inc.; Biomedical Advanced Research and Development Authority; US Department of Defense; and PCI Biotech. The company operates in the United States, Holland, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is headquartered in Kvistgård, Denmark. Receive BVNRY News and Ratings via Email Sign-up to receive the latest news and ratings for BVNRY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical SymbolOTCMKTS:BVNRY CUSIPN/A Webwww.bavarian-nordic.com Phone45-3326-8383 Debt Debt-to-Equity Ratio0.18 Current Ratio5.35 Quick Ratio5.07 Price-To-Earnings Trailing P/E Ratio32.10 Forward P/E Ratio-15.26 P/E GrowthN/A Sales & Book Value Annual Sales$208.06 million Price / Sales4.34 Cash Flow$0.3727 per share Price / Cash24.98 Book Value$3.96 per share Price / Book2.35 Profitability EPS (Most Recent Fiscal Year)$0.29 Net Income$27.54 million Net Margins-18.41% Return on Equity-6.60% Return on Assets-5.23% Miscellaneous Employees437 Outstanding Shares96,930,000Market Cap$837.84 million BAVARIAN NORDIC/S (OTCMKTS:BVNRY) Frequently Asked Questions What is BAVARIAN NORDIC/S's stock symbol? BAVARIAN NORDIC/S trades on the OTCMKTS under the ticker symbol "BVNRY." How were BAVARIAN NORDIC/S's earnings last quarter? BAVARIAN NORDIC/S (OTCMKTS:BVNRY) posted its quarterly earnings data on Thursday, August, 16th. The company reported ($0.18) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.16) by $0.02. The company had revenue of $13.83 million for the quarter, compared to analyst estimates of $10.40 million. BAVARIAN NORDIC/S had a negative return on equity of 6.60% and a negative net margin of 18.41%. View BAVARIAN NORDIC/S's Earnings History. When is BAVARIAN NORDIC/S's next earnings date? BAVARIAN NORDIC/S is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for BAVARIAN NORDIC/S. Who are some of BAVARIAN NORDIC/S's key competitors? Some companies that are related to BAVARIAN NORDIC/S include China Biologic Products (CBPO), Acceleron Pharma (XLRN), argenx (ARGX), Aerie Pharmaceuticals (AERI), Repligen (RGEN), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Spark Therapeutics (ONCE), Denali Therapeutics (DNLI), Atara Biotherapeutics (ATRA), Solid Biosciences (SLDB), Rubius Therapeutics (RUBY) and Editas Medicine (EDIT). Who are BAVARIAN NORDIC/S's key executives? BAVARIAN NORDIC/S's management team includes the folowing people: Dr. Paul Chaplin, CEO & Pres (Age 51)Mr. Henrik Birk, COO & Exec. VP (Age 44)Dr. Christopher R. Heery M.D., Chief Medical OfficerDr. Tommi Kainu M.D., Ph.D., Exec. VP, Chief Bus. Officer & Member of the Exec. Management (Age 45)Mr. Claus Bo Madsen, QAC Mang. Has BAVARIAN NORDIC/S been receiving favorable news coverage? Media stories about BVNRY stock have been trending somewhat positive on Friday, according to Accern. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. BAVARIAN NORDIC/S earned a daily sentiment score of 0.18 on Accern's scale. They also gave media stories about the company an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for BAVARIAN NORDIC/S. How do I buy shares of BAVARIAN NORDIC/S? Shares of BVNRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is BAVARIAN NORDIC/S's stock price today? One share of BVNRY stock can currently be purchased for approximately $9.31. How big of a company is BAVARIAN NORDIC/S? BAVARIAN NORDIC/S has a market capitalization of $837.84 million and generates $208.06 million in revenue each year. The company earns $27.54 million in net income (profit) each year or $0.29 on an earnings per share basis. BAVARIAN NORDIC/S employs 437 workers across the globe. How can I contact BAVARIAN NORDIC/S? BAVARIAN NORDIC/S's mailing address is Hejreskovvej 10A, Kvistgaard G7, 3490. The company can be reached via phone at 45-3326-8383 or via email at [email protected] MarketBeat Community Rating for BAVARIAN NORDIC/S (OTCMKTS BVNRY)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 121 (Vote Outperform)Underperform Votes: 76 (Vote Underperform)Total Votes: 197MarketBeat's community ratings are surveys of what our community members think about BAVARIAN NORDIC/S and other stocks. Vote "Outperform" if you believe BVNRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BVNRY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/21/2018 by MarketBeat.com StaffFeatured Article: Dividend Stocks - Are They Right For You?